Suven Life Sciences · NSE: SUVEN · BSE: 530239

Q3 FY20 results · Oct–Dec 2019

Suven Life Sciences reported revenue from operations of ₹2.77 crore and net loss of ₹22.81 crore for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	2.77	—	—	274.31	−99.0%
Other income	5.86	—	—	5.59	+4.8%
Total income	8.63	—	—	279.90	−96.9%
Profit before tax	(22.77)	—	—	99.66	Turned loss
Net profit for the period	(22.81)	—	—	63.31	Turned loss
EPS, basic (₹)	(1.79)	—	—	4.97	Turned loss
Net margin (%)	-822.8	—		23.1

Standalone · ₹ crore
Item	Q3 FY20	Q3 FY19	YoY	Q2 FY20	QoQ
Revenue from operations	2.77	129.02	−97.9%	274.31	−99.0%
Other income	5.86	5.76	+1.6%	5.59	+4.8%
Total income	8.63	134.78	−93.6%	279.90	−96.9%
Profit before tax	(4.46)	35.22	Turned loss	108.67	Turned loss
Net profit for the period	(4.50)	25.23	Turned loss	72.32	Turned loss
EPS, basic (₹)	(0.35)	1.98	Turned loss	5.68	Turned loss
Net margin (%)	-162.4	19.6		26.4

Consolidated

Standalone